Please login to the form below

Not currently logged in
Email:
Password:

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

Finally, PD-1 latecomers Sanofi and Regeneron will share the first results from an early-stage trial of their candidate cemiplimab in NSCLC at ASCO, as a monotherapy in patients who

Latest news

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    Schleifer spent a sizeable portion of the conference call talking up Regeneron’s emerging position in immuno-oncology, currently led by Sanofi-partnered PD-1 inhibitor cemiplimab, which is due for ... The company has chosen a first indication for

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    Regeneron-partnered cemiplimab is the first of the new wave of checkpoint inhibitors to be filed for CSCC, and also picked up a breakthrough designation from the FDA last September. ... Sanofi has three trials of cemiplimab either ongoing or planned in

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... Cemiplimab is one of nine drugs expected to be filed by Sanofi before the middle of next year, according to the

  • Sanofi and Regeneron ramp up immuno-oncology collaboration Sanofi and Regeneron ramp up immuno-oncology collaboration

    Sanofi and Regeneron ramp up immuno-oncology collaboration. Will put an additional $1bn in investigational candidate cemiplimab. ... Sanofi and Regeneron are set to give the development programme for their immuno-oncology candidate cemiplimab a $1bn boost

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    Sanofi/Regeneron start first filings for PD-1 drug cemiplimab. The pharma partners begin with a skin cancer filing to the US FDA. ... This is the largest prospective study ever conducted in this disease, and we are pleased that many people were able to

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics